Zulassungsempfehlung : Dapagliflozin als erste orale Add-on-Therapie bei Typ -1-Diabetes
DEPICT-1-Studie mit Dapagliflozin: Mögliche Zusatztherapie
Forxiga® 5 mg 28 St - shop-apotheke.com
JDRF Reports: European Commission Has Approved Forxiga for T1D
Dapagliflozin effective in treating type 1 diabetes
Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination – touchENDOCRINOLOGY
Dapagliflozin für Typ-1-Diabetiker empfohlen
Typ-2-Diabetes und Herz-Kreislauf-Risiko: Dapagliflozin hat positive Effekte auch in der kardiovaskulären Primärprävention
Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination – touchENDOCRINOLOGY
Exploring the potential of dapagliflozin in type 1 diabetes: phase 2a pilot study - Media Centre | EASD
Dapagliflozin zur Therapie des Typ-2-Diabetes - 03 - 2013 - Heftarchiv - AMT
Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials - The Lancet Diabetes & Endocrinology
Forxiga: Keine Zulassung mehr bei Typ-1-Diabetes | Apotheken Umschau
Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice - ScienceDirect
Our response to the withdrawal of dapagliflozin (Forxiga) for type 1 diabetes - JDRF, the type 1 diabetes charity
Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination – touchENDOCRINOLOGY
Pharmakovigilanz: Gliflozin-Nutzen überwiegt das Risiko
Forxiga® (Dapagliflozin)
Zulassungsänderung - Keine Anwendung von Dapagliflozin bei Typ-1-Diabetes mellitus • diabetologie-online
Diabetische Ketoazidose unter Forxiga: Dapagliflozin verliert seine Typ-1- Diabetes-Indikation
Wichtige Sicherheitsinformationen zum Risiko einer Diabetischen Ketoazidose (DKA) unter Forxiga 5 mg (Dapagliflozin) zur Anwen
Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study - The Lancet Diabetes & Endocrinology
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial -
